Pregabalin is a gamma‐aminobutyric acid analogue registered and subsidised for the treatment of neuropathic pain in Australia. Despite pre-clinical evidence of low abuse potential, there have been increasing reports of extra-medical use and overdose deaths involving pregabalin. This presentation aimed to describe patterns of pregabalin use among an Australian sample of people who inject drugs (PWID), and identify sociodemographic, substance use, and mental/physical health correlates of prescribed and non-prescribed use.

Resources

Author(s)

Rachel Sutherland, Paul Dietze, Natasa Gisev, Raimondo Bruno, Sonja Memedovic, Gabrielle Campbell, Amy Peacock
Date Commenced
20 Nov 2019
Resource Type
General